On March 21, 2022 KIYATEC, the leader in clinically correlated, published functional precision oncology technology reported that CEO Matt Gevaert, Ph.D., will present virtually at the KeyBanc Capital Markets’ Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 1:30 PM Eastern Time (Press release, KIYATEC, MAR 21, 2022, View Source [SID1234610494]). KIYATEC’s participation includes virtual one-on-one meetings with investors during the two-day event which begins Tuesday, March 22nd.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leveraging its innovative 3D cell culture technology platform for both clinical and pre-clinical use, KIYATEC recently introduced its first commercial assay in the US, 3D Predict Glioma. The Company is adding commercial and business development capabilities to secure payer reimbursement and coverage while generating demand for these services among clinical and pre-clinical customers. Recently, KIYATEC began a facilities expansion to support the Company’s five-year growth plans to increase laboratory capacity and accelerate product development.